Castle Biosciences (CSTL) Gross Profit (2018 - 2026)

Castle Biosciences has disclosed Gross Profit across 9 years of filings, most recently posting $79.8 million for Q2 2026.

• In Q2 2026, Gross Profit rose 16.46% year-over-year to $79.8 million; the TTM figure through Jun 2026 stood at $276.0 million (down 1.58% YoY), while the FY2025 annual figure was $273.2 million, changed 0.49% from the prior year.
• Gross Profit came in at $79.8 million for Q2 2026 at Castle Biosciences, up from $63.1 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $79.8 million in Q2 2026 to a low of $20.9 million in Q1 2022.
• Average Gross Profit over 5 years is $53.8 million, with a median of $61.1 million recorded in 2024.
• Year-over-year, Gross Profit surged 86.33% in 2023 and decreased 11.81% in 2026.
• Over 5 years, Gross Profit stood at $28.8 million in 2022, then soared by 86.33% to $53.7 million in 2023, then surged by 30.6% to $70.1 million in 2024, then declined by 2.04% to $68.7 million in 2025, then climbed by 16.23% to $79.8 million in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were $79.8 million in Q2 2026, $63.1 million in Q1 2026, and $68.7 million in Q4 2025.